코오롱티슈진
950160KOSDAQ기초 의약물질 제조업42.9 / 100
Reference Date: 2026-07-24
Company InformationBased on 2025 Annual Report
Business Overview
Koongtishujin is a biotech company developing cell gene therapy drugs using its TG-C platform, currently conducting Phase III clinical trials for knee osteoarthritis and Phase II trials for hip osteoarthritis. As of July 2024, the Phase III trial for knee osteoarthritis has enrolled 1,066 patients. The company also operates a complex distribution business, selling health supplements, cosmetics, and wines through its W-store and L&B segments.
Number of Employees
58people
Average Salary
163.1M KRW
Score Calculation Basis
Detailed Financial Score
31.2x industry avg (excellent)
In line with industry avg
Avg ▲14.3% (2-year basis)
Avg ▼0.0% (2-year basis)
Avg ROE -77.0% (declining, 3yr)
Detailed News Sentiment
- Negative삼전닉스 레버리지 쏠림에 코스닥 거래대금 반토막
코스닥 거래대금 감소로 코오롱티슈진의 직접적인 수익성에 부정적 영향 예상
- Negative“순식간에 주가 3분의1 토막, 빠져나올 틈도 안줘”…코오롱티슈진 .....
코오롱티슈진의 골관절염 치료제 임상 실패로 주가가 급격히 하락했다.
- Negative코오롱티슈진 TG-C 美 3상 실패에 이틀째 '下'(종합)
코오롱티슈진의 TG-C 치료제 미국 임상 3상 실패로 인해 주가 하락이 예상됩니다.
Detailed Momentum
Near 52w low (0%, downtrend)
1m -79.18% (strong drop)
Volume increasing
Detailed Disclosure
- Neutral투자판단관련주요경영사항(임상시험결과) (TGC 15302 Study 탑라인 데이터 )2026-07-20
- Negative[기재정정]소송등의제기ㆍ신청(일정금액이상의청구)2026-07-09
- Negative소송등의판결ㆍ결정(일정금액이상의청구)2026-07-03
- Negative[기재정정]소송등의제기ㆍ신청(일정금액이상의청구)2026-07-01
